drugset
drugset / Trial / NCT06962280

A Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight

NCT06962280 ↗

Phase 3 Active not recruiting 465 enrolled Eli Lilly and Company
RandomizedParallel-groupDouble-blindTreatment

Summary

The main purpose of this study is to find out how well and how safely tirzepatide works long-term in adults who have type 1 diabetes and obesity or overweight. Participation in the study will last about 20 months.

Timeline

Start
2025-05-12
Primary completion
2026-11
Completion
2027-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Tirzepatide Peptide — Subcutaneous

Indications

obesity disorder type 1 diabetes mellitus